Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherClinical Investigations (Human)

QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY

Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher and Hebert Alberto Vargas
Journal of Nuclear Medicine January 2021, jnumed.120.256602; DOI: https://doi.org/10.2967/jnumed.120.256602
Andreas G. Wibmer
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas G. Wibmer
Michael J. Morris
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mithat Gonen
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junting Zheng
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hedvig Hricak
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Larson
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard I. Scher
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hebert Alberto Vargas
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

RATIONALE: New biomarkers for metastatic prostate cancer are needed. The aim of this study was to evaluate the prognostic value of FDG-PET whole body tumor burden parameters in patients with metastatic prostate cancer who received first line abiraterone or enzalutamide therapy. METHODS: Retrospective study of patients with metastatic castration-sensitive (mCSPC, n = 25) and metastatic castration-resistant prostate cancer (mCRPC, n = 71) who underwent 18F-FDG-PET/CT within 90 days before first-line treatment with abiraterone or enzalutamide at a tertiary care academic cancer center. Whole-body tumor burden on PET/CT was quantified as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) and correlated with overall survival (OS) probabilities using Kaplan-Meier curves and Cox models. RESULTS: The median follow-up in survivors was 56.3 months (IQR: 37.7, 66.8); the median OS for patients with mCRPC and mCSPC was 27.8 and 76.1 months (p<.001). On univariate analysis, the OS probability of mCRPC patients was significantly associated with plasma levels of alkaline phosphatase (HR: 1.90, p<.001) and lactate dehydrogenase (HR: 1.01, p<.001), hemoglobin levels (HR: 0.80, P = .013), whole body SUVmax (HR: 1.14, p<0.001), the number of FDG-avid metastases (HR: 1.08, p<0.001), whole body MTV (HR: 1.86, p<.001) and TLG (HR: 1.84, p<.001). In multivariable analysis with stepwise variable selection, hemoglobin levels (HR: 0.81, P = 0.013) and whole-body TLG (HR: 1.88, p<.001) were independently associated with OS. In mCSPC patients, no significant association was observed between these variables and OS. CONCLUSION: In patients with mCRPC receiving first-line treatment with abiraterone or enzalutamide, FDG PET WB TLG is independently associated with OS and might be used as quantitative prognostic imaging biomarker.

  • Genitourinary
  • Molecular Imaging
  • Oncology: GU
  • PET/CT
  • 18F-fluoro-desoxy-glucose positron-emission tomography computed tomography
  • abiraterone; enzalutamide
  • metastatic prostate cancer
  • overall survival
  • whole-body tumor burden
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Jan 2021, jnumed.120.256602; DOI: 10.2967/jnumed.120.256602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Jan 2021, jnumed.120.256602; DOI: 10.2967/jnumed.120.256602
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis
  • Simulation of low dose protocols for myocardial perfusion 82Rubidium imaging
Show more Clinical Investigations (Human)

Clinical (Oncology: GU)

  • Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
  • A novel time-activity information sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT imaging post-177Lu-DOTATATE
Show more Clinical (Oncology: GU)

Similar Articles

Keywords

  • Genitourinary
  • molecular imaging
  • oncology: GU
  • PET/CT
  • 18F-fluoro-desoxy-glucose positron-emission tomography computed tomography
  • abiraterone; enzalutamide
  • metastatic prostate cancer
  • overall survival
  • whole-body tumor burden
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire